This narrative review consolidates evidence that SIRT1-4 improve metabolic control in adipose, liver, muscle, and pancreas (indirect cardiovascular benefit), while SIRT1 and SIRT7 act directly on heart and vessel wall: SIRT1 deacetylates eNOS (Lys496/506), FoxO1, and p53, and represses AT1R; SIRT7-deficient mice develop hypertrophy and inflammatory cardiomyopathy via p53 hyperacetylation . The authors' distinctive contribution is framing sirtuin activity as NAD+-supply-limited: PARP1 activation during heart failure depletes NAD+, and Nampt/Nmnat overexpression preserves SIRT1 activity and cell survival .
Quantitative support for direct sirtuin activation by resveratrol later emerged but is substrate-specific and modest: at 0.2 mM resveratrol activates Sirt5 ~2.5-fold on FdL1 yet inhibits Sirt3; piceatannol activates Sirt5 with EC50 0.076 Β± 0.02 mM . The paper itself flags the key controversy correctly, noting that polyphenol effects may reflect stress-response hormesis rather than direct activation, and that assay artifacts plague SIRT1 activator claims .
The review's Nampt/NAD+ thesis proved prescient: NAD+ biosynthesis is now framed as a circadian, inter-organ system (eNAMPT/NMN axis) relevant to cardiac and metabolic aging , and a recent preprint links a FNDC1-NAMPT-NAD axis to arterial disease and vascular calcification, extending the vascular-NAMPT connection the authors established in smooth muscle cells .
The review omits NAD+ consumer competition (PARP/CD38 as systemic NAD+ sinks) and circadian regulation, which later proved central . All cited in vivo data are mouse/rat/monkey; no human outcome trials existed, and downstream human resveratrol/NMN trials have underdelivered on cardiovascular endpoints β data showing strain-dependent SIRT1 knockout phenotypes (which the authors did acknowledge) was an early warning. Findings showing NMN/NR fail to extend lifespan beyond redox-perturbation effects would weaken the supply-limitation model . Confidence: moderate β strong mechanistic curation, weak translational evidence base.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.